Susan Quinn

发表

A Thermal Imaging Solution for Early Detection of Pre-ulcerative Diabetic Hotspots

Chris D. Nugent, Ian Cleland, Susan Quinn, 2019, 2019 41st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

Susan Quinn, Revathi Ananthakrishnan, Thomas J Lynch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer

Susan Quinn, Gunnar Folprecht, Josep Tabernero, 2008, Clinical Cancer Research.